Image may be NSFW.
Clik here to view.
President Donald Trump’s administration took aim at drug-pricing reform this month by holding listening sessions with industry groups and advocates. His administration is pursuing actions it can take with and without Congress to combat the industry’s high drug prices, according to a report from The Hill.
The pharmaceutical industry, traditionally a powerful lobbying force on Capitol Hill, now faces unpredictability – it is not yet clear what the president and his team will do or how impactful the decisions will be.
Get the full story at our sister site, Drug Delivery Business News.
The post Trump considers drug-pricing reform with input from industry groups, advocates appeared first on MassDevice.
